Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)

This study is for the treatment of non-small cell lung cancer.

Primary disease category: Cancer

Secondary disease categories: Cancer, Lung Cancer

Protocol number: A081105

Projected enrollment dates: October 2015 to February 2017

Official study title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)

ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02193282

You are here

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR)Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST) (A081105)